alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
§ 137.416 Do §§ 137.415 through 137.436 apply to any other disputes? No, §§ 137.415 through 137.436 only apply to decisions listed in § 137.415. Specifically, §§ 137.415 through 137.436 do not apply to any other dispute, including, but not limited to: ( a ) Disputes arising under the terms of a compact, funding agreement, or construction project agreement that has been awarded;
( b ) Disputes arising from immediate reassumptions under section 507(a)(2)(C) of the Act [25 U.S.C. 458aaa-6(a)(2)(C)] and § 137.261 and 137.262, which are covered under § 137.440 through 137.445.
( c ) Other post-award contract disputes, which are covered under § 137.412.
( d ) Denials under the Freedom of Information Act, 5 U.S.C. 552, which may be appealed under 45 CFR part 5.
( e ) Decisions relating to the award of grants under section 503(e) of the Act [25 U.S.C. 458aaa-2(e)], which may be appealed under 45 CFR part 5.
# C_2005273EN.01000401.xml

| 4.11.2005 | EN | Official Journal of the European Union | C 273/4 |
| --- | --- | --- | --- |

4.11.2005

EN

Official Journal of the European Union

C 273/4

---

Euro exchange rates (1)

1

2 November 2005

(2005/C 273/04)

1 euro=

1 euro

| | Currency | Exchange rate |
| --- | --- | --- |
| USD | US dollar | 1,1992 |
| JPY | Japanese yen | 140,26 |
| DKK | Danish krone | 7,4635 |
| GBP | Pound sterling | 0,67895 |
| SEK | Swedish krona | 9,5973 |
| CHF | Swiss franc | 1,5422 |
| ISK | Iceland króna | 71,67 |
| NOK | Norwegian krone | 7,7850 |
| BGN | Bulgarian lev | 1,9559 |
| CYP | Cyprus pound | 0,5737 |
| CZK | Czech koruna | 29,551 |
| EEK | Estonian kroon | 15,6466 |
| HUF | Hungarian forint | 250,39 |
| LTL | Lithuanian litas | 3,4528 |
| LVL | Latvian lats | 0,6965 |
| MTL | Maltese lira | 0,4293 |
| PLN | Polish zloty | 3,9690 |
| RON | Romanian leu | 3,6559 |
| SIT | Slovenian tolar | 239,50 |
| SKK | Slovak koruna | 39,000 |
| TRY | Turkish lira | 1,6177 |
| AUD | Australian dollar | 1,6192 |
| CAD | Canadian dollar | 1,4153 |
| HKD | Hong Kong dollar | 9,2971 |
| NZD | New Zealand dollar | 1,7329 |
| SGD | Singapore dollar | 2,0348 |
| KRW | South Korean won | 1 246,69 |
| ZAR | South African rand | 8,0067 |
| CNY | Chinese yuan renminbi | 9,6957 |
| HRK | Croatian kuna | 7,3930 |
| IDR | Indonesian rupiah | 12 063,95 |
| MYR | Malaysian ringgit | 4,528 |
| PHP | Philippine peso | 65,620 |
| RUB | Russian rouble | 34,3180 |
| THB | Thai baht | 48,969 |

Currency

Exchange rate

USD

US dollar

1,1992

JPY

Japanese yen

140,26

DKK

Danish krone

7,4635

GBP

Pound sterling

0,67895

SEK

Swedish krona

9,5973

CHF

Swiss franc

1,5422

ISK

Iceland króna

71,67

NOK

Norwegian krone

7,7850

BGN

Bulgarian lev

1,9559

CYP

Cyprus pound

0,5737

CZK

Czech koruna

29,551

EEK

Estonian kroon

15,6466

HUF

Hungarian forint

250,39

LTL

Lithuanian litas

3,4528

LVL

Latvian lats

0,6965

MTL

Maltese lira

0,4293

PLN

Polish zloty

3,9690

RON

Romanian leu

3,6559

SIT

Slovenian tolar

239,50

SKK

Slovak koruna

39,000

TRY

Turkish lira

1,6177

AUD

Australian dollar

1,6192

CAD

Canadian dollar

1,4153

HKD

Hong Kong dollar

9,2971

NZD

New Zealand dollar

1,7329

SGD

Singapore dollar

2,0348

KRW

South Korean won

1 246,69

ZAR

South African rand

8,0067

CNY

Chinese yuan renminbi

9,6957

HRK

Croatian kuna

7,3930

IDR

Indonesian rupiah

12 063,95

MYR

Malaysian ringgit

4,528

PHP

Philippine peso

65,620

RUB

Russian rouble

34,3180

THB

Thai baht

48,969

---

(1)

1

Source: reference exchange rate published by the ECB.

Source:

---
§ 405.906 Parties to the initial determinations, redeterminations, reconsiderations, hearings, and reviews. ( a ) *Parties to the initial determination.* The parties to the initial determination are the following individuals and entities: ( 1 ) A beneficiary who files a claim for payment under Medicare Part A or Part B or has had a claim for payment filed on his or her behalf, or in the case of a deceased beneficiary, when there is no estate, any person obligated to make or entitled to receive payment in accordance with part 424, subpart E of this chapter. Payment by a third party payer does not entitle that entity to party status.
( 2 ) A supplier who has accepted assignment for items or services furnished to a beneficiary that are at issue in the claim.
( 3 ) A provider of services who files a claim for items or services furnished to a beneficiary.
( 4 ) An applicable plan for an initial determination under § 405.924(b)(16) where Medicare is pursuing recovery directly from the applicable plan. The applicable plan is the sole party to an initial determination under § 405.924(b)(16) (that is, where Medicare is pursuing recovery directly from the applicable plan).
( b ) *Parties to the redetermination, reconsideration, proceedings on a request for hearing, and Council review.* The parties to the redetermination, reconsideration, proceedings on a request for hearing, and Council review are— ( 1 ) The parties to the initial determination in accordance with paragraph (a) of this section, except under paragraph (a)(1) of this section where a beneficiary has assigned appeal rights under § 405.912;
( 2 ) A State agency in accordance with § 405.908;
( 3 ) A provider or supplier that has accepted an assignment of appeal rights from the beneficiary according to § 405.912;
( 4 ) A non-participating physician not billing on an assigned basis who, in accordance with section 1842(l) of the Act, may be liable to refund monies collected for services furnished to the beneficiary because those services were denied on the basis of section 1862(a)(1) of the Act; and
( 5 ) A non-participating supplier not billing on an assigned basis who, in accordance with sections 1834(a)(18) and 1834(j)(4) of the Act, may be liable to refund monies collected for items furnished to the beneficiary.
( c ) *Appeals by providers and suppliers when there is no other party available.* If a provider or supplier is not already a party to the proceeding in accordance with paragraphs (a) and (b) of this section, a provider of services or supplier may appeal an initial determination relating to services it rendered to a beneficiary who subsequently dies if there is no other party available to appeal the determination. This paragraph (c) does not apply to an initial determination with respect to an applicable plan under § 405.924(b)(16).
[70 FR 11472, Mar. 8, 2005, as amended at 80 FR 10617, Feb. 27, 2015; 82 FR 5106, Jan. 17, 2017]
#### § 137.433 Is the recommended decision always final?

No, any party to the appeal may file precise and specific written objections to the recommended decision, or any other comments, within 30 days of receiving the recommended decision. Objections must be served on all other parties. The recommended decision shall become final for the Secretary 30 days after the Indian Tribe receives the ALJs recommended decision, unless a written statement of objections is filed with the Secretary during the 30-day period. If no party files a written statement of objections within 30 days, the recommended decision shall become final for the Secretary.
# C_2005171EN.01002801.xml

| 9.7.2005 | EN | Official Journal of the European Union | C 171/28 |
| --- | --- | --- | --- |

9.7.2005

EN

Official Journal of the European Union

C 171/28

---

Action brought on on 13 April 2005 by Johan de Geest against Council of the European Union

(Case T- 164/05)

(2005/C 171/46)

Language of the case: French

An action against the Council of the European Union was brought before the Court of First Instance of the European Communities on 13 April 2005 by Johan de Geest, residing in Rhode-St-Genèse (Belgium), represented by Sébastien Orlandi, Xavier Martin, Albert Coolen, Jean-Noël Louis and Etienne Marchal, lawyers, with an address for service in Luxembourg.

The applicant claims that the Court should:

| — | annul the decision to appoint him as an official of the European Communities in that it fixes his grade on recruitment at A*6, pursuant to Article 12 of Annex XIII to the Staff Regulations; |
| --- | --- |

—

annul the decision to appoint him as an official of the European Communities in that it fixes his grade on recruitment at A*6, pursuant to Article 12 of Annex XIII to the Staff Regulations;

| — | order the Council to pay the costs. |
| --- | --- |

—

order the Council to pay the costs.

Pleas in law and main arguments

The applicant was a candidate in internal competition CONSEIL/A/273 held to fill a post as doctor in grade A6 or A7. The applicant was successful in the competition and was appointed in grade A*6. The applicant contests that decision, claiming that he should have been appointed in grade A*8, A*9 or A*10, which, under the new system, correspond to the former grades referred to in the notification of competition.

In support of his action, the applicant claims that the Council fixed his grade on recruitment without having regard to the notification of vacancy and, accordingly, breached Articles 29 and 31 of the Staff Regulations and also the principle of legitimate expectations. In that context, the applicant also claims that article 12 of Article XIII to the Staff Regulations, which the Council applied when fixing his grade on recruitment, unlawfully alters the framework of legality of the recruitment procedure.

---
# Materials Not Included in **Airworthiness Directive (AD) Docket**

Docket Number: F AA- 2012 - 0594 Directorate Identifier: 2012NM019AD

84 - 27 - 57 --- 7/22/11

Name/Description of Item(s) Not Included in FDMS Docket and Maintained in the Supplemental AD Docket 

### MA **Y BE VIEWED AT:** Federal Aviation Administration

Transport Airplane Directorate Rules Docket 1601 Lind Ave. SW., Renton, WA 98057 425.227.1221 **DURING THE HOURS OF:** 9 a.m. and 3 p.m., Monday through Friday, except Federal holidays. Form Date: 0 3/05/2008
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Justice

###### Drug Enforcement Administration

Pursuant to Section 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on June 26, 2009, Noramco Inc., Division of Ortho-McNeil, Inc., 500 Swedes Landing Road, Wilmington, Delaware 19801-4417, made application by letter to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of Noroxymorphone (9668), a basic class of controlled substance listed in schedule II.

The company plans to bulk manufacture the listed controlled substance as a reference standard for distribution to its customers which are analytical laboratories.

Any other such applicant, and any person who is presently registered with DEA to manufacture such a substance, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

                    Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control,                     **Federal Register**                     Representative (ODL), 8701 Morrissette Drive, Springfield, VA 22152; and must be filed no later than November 9, 2009.                

Dated: August 28, 2009.

Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. E9-21524 Filed 9-4-09; 8:45 am]

BILLING CODE 4410-09-P
Editorial Note on Part 413
Editorial Note: Nomenclature changes to part 413 appear at 76 FR 50537, August 22, 2014.

§ 413.90 Research costs. ( a ) *Principle.* Costs incurred for research purposes, over and above usual patient care, are not includable as allowable costs.
( b ) *Application.* ( 1 ) There are numerous sources of financing for health-related research activities. Funds for this purpose are provided under many Federal programs and by other tax-supported agencies. Also, many foundations, voluntary health agencies, and other private organizations, as well as individuals, sponsor or contribute to the support of medical and related research. Funds available from such sources are generally ample to meet basic medical and hospital research needs. A further consideration is that quality review should be assured as a condition of governmental support for research. Provisions for such review would introduce special difficulties in the Medicare programs.
( 2 ) If research is conducted in conjunction with, and as a part of, the care of patients, the costs of usual patient care and studies, analyses, surveys, and related activities to serve the provider's administrative and program needs are allowable costs in the determination of payment under Medicare.
[51 FR 34793, Sept. 30, 1986, as amended at 61 FR 63748, Dec. 2, 1996]
HomeOffice of the SpokespersonPress Releases...Deputy Secretary Sherman’s Meeting with Republic of Korea First Vice Foreign Minister Cho

# 									Deputy Secretary Sherman’s Meeting with Republic of Korea First Vice Foreign Minister Cho							

Readout

Office of the Spokesperson

June 7, 2022

The following is attributable to Spokesperson Ned Price:

Deputy Secretary of State Wendy Sherman met today with Republic of Korea (ROK) First Vice Foreign Minister Cho Hyundong to discuss opportunities to build on the momentum from the May 21 Summit between President Biden and President Yoon.  They discussed the importance of strengthening trilateral ties with Japan, including through their June 8 trilateral meeting with Japanese Vice Foreign Minister Mori Takeo, to uphold the rules-based international order and to achieve the complete denuclearization of the Korean Peninsula.  The Deputy Secretary and First Vice Foreign Minister condemned recent unlawful ballistic missile launches by the DPRK and expressed concern over Pyongyang’s increasingly provocative behavior.

Deputy Secretary Sherman and First Vice Foreign Minister Cho also discussed the importance of maintaining peace and stability in the Taiwan Strait, as well as international efforts to hold Putin to account for his unprovoked, unjustified, and unconscionable war against Ukraine.  The Deputy Secretary and Vice Foreign Minister also spoke about cooperating to address climate change, promoting resilient supply chains, and working together to increase gender equity and equality.

Tags

Bureau of East Asian and Pacific AffairsBureau of European and Eurasian AffairsClimate ChangeDeputy Secretary of StateJapanNorth KoreaOffice of the SpokespersonPeaceRegional IssuesRussiaSecuritySouth KoreaTaiwanUkraine

Back to Top
[Federal Register Volume 74, Number 172 (Tuesday, September 8, 2009)]
[Notices]
[Page 46228]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E9-21541]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Importer of Controlled Substances; Notice of Application

    Pursuant to 21 U.S.C. 958(i), the Attorney General shall, prior to 
issuing a registration under this Section to a bulk manufacturer of a 
controlled substance in schedule I or II and prior to issuing a 
regulation under 21 U.S.C. 952(a)(2) authorizing the importation of 
such a substance, provide manufacturers holding registrations for the 
bulk manufacture of the substance an opportunity for a hearing.
    Therefore, in accordance with Title 21 Code of Federal Regulations 
(CFR), 1301.34(a), this is notice that on July 8, 2009, Clinical 
Supplies Management, Inc., 342 42nd Street South, Fargo, North Dakota 
58103, made application by renewal to the Drug Enforcement 
Administration (DEA) to be registered as an importer of Sufentanil 
(9740), a basic class of controlled substance listed in schedule II.
    The company plans to import the listed controlled substance with 
the sole purpose of packaging, labeling, and distributing to customers 
which are qualified clinical sites conducting clinical trials under the 
auspices of an FDA-approved clinical study.
    Any bulk manufacturer who is presently, or is applying to be, 
registered with DEA to manufacture such basic class of controlled 
substance may file comments or objections to the issuance of the 
proposed registration and may, at the same time, file a written request 
for a hearing on such application pursuant to 21 CFR 1301.43 and in 
such form as prescribed by 21 CFR 1316.47.
    Any such comments or objections should be addressed, in 
quintuplicate, to the Drug Enforcement Administration, Office of 
Diversion Control, Federal Register Representative (ODL), 8701 
Morrissette Drive, Springfield, VA 22152; and must be filed no later 
than October 8, 2009.
    This procedure is to be conducted simultaneously with, and 
independent of, the procedures described in 21 CFR 1301.34(b), (c), 
(d), (e) and (f). As noted in a previous notice published in the 
Federal Register on September 23, 1975, (40 FR 43745-46), all 
applicants for registration to import a basic class of any controlled 
substance in schedule I or II are and will continue to be required to 
demonstrate to the Deputy Assistant Administrator, Office of Diversion 
Control, Drug Enforcement Administration, that the requirements for 
such registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and 
21 CFR 1301.34(b), (c), (d), (e), and (f) are satisfied.

    Dated: August 28, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. E9-21541 Filed 9-4-09; 8:45 am]
BILLING CODE 4410-09-P
IB

House Calendar No. 228

104TH CONGRESS

2D SESSION H. R. 3029

[Report No. 104–588]

To designate the United States courthouse in Washington, District of

Columbia, as the ‘‘E. Barrett Prettyman United States Courthouse’’.

IN THE HOUSE OF REPRESENTATIVES

MARCH 6, 1996

Mr. DAVIS (for himself and Ms. NORTON) introduced the following bill; which

was referred to the Committee on Transportation and Infrastructure

MAY 21, 1996

Referred to the House Calendar and ordered to be printed

A BILL

To designate the United States courthouse in Washington,

District of Columbia, as the ‘‘E. Barrett Prettyman

United States Courthouse’’.

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled,

3 SECTION 1. DESIGNATION OF COURTHOUSE.

4 The United States courthouse located at 3rd Street

5 and Constitution Avenue, Northwest, in Washington, Dis-
2

•HR 3029 RH

1 trict of Columbia, shall be designated and known as the

2 ‘‘E. Barrett Prettyman United States Courthouse’’.

3 SEC. 2. REFERENCES.

4 Any reference in a law, map, regulation, document,

5 paper, or other record of the United States to the United

6 States courthouse referred to in section 1 shall be deemed

7 to be a reference to the ‘‘E. Barrett Prettyman United

8 States Courthouse’’.

House Calendar No. 228

104TH CONGRESS

2D SESSION H. R. 3029

[Report No. 104–588]

A BILL

To designate the United States courthouse in

Barrett Prettyman United States Courthouse’’.Washington, District of Columbia, as the ‘‘E.

MAY 21, 1996

Referred to the House Calendar and ordered to be

printed
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM STERLING GAS
DRILLING FUND 1982 FORM 10-K AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO
SUCH FINANCIAL STATEMENTS.
</LEGEND>
       
<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          DEC-31-1998
<PERIOD-END>                               DEC-31-1998
<CASH>                                              20
<SECURITIES>                                         0
<RECEIVABLES>                                        0
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                                    20
<PP&E>                                      12,436,895
<DEPRECIATION>                            (11,747,491)
<TOTAL-ASSETS>                                 689,404
<CURRENT-LIABILITIES>                          262,068
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                             0     
<OTHER-SE>                                     427,356<F1>
<TOTAL-LIABILITY-AND-EQUITY>                   689,424
<SALES>                                        322,770
<TOTAL-REVENUES>                               322,770
<CGS>                                          299,301
<TOTAL-COSTS>                                  299,301      
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                                      0
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                    23,469
<EPS-PRIMARY>                                     1.00<F2>
<EPS-DILUTED>                                       .0
<FN>
<F1>OTHER - SE IS COMPOSED OF PARTNERSHIP EQUITY.
<F2>EPS - PRIMARY IS BASED UPON LIMITED PARTNERS SHARE OF NET INCOME DIVIDED BY THE
OUTSTANDING PARTNERSHIP UNITS OF 14,370.
</FN>
        

</TABLE>